BUZZ-Genprex rises as diabetes gene therapy shows promise in animal tests

Reuters01-06
BUZZ-Genprex rises as diabetes gene therapy shows promise in animal tests

** Shares of drug developer Genprex GNPX.O rise 7.8% to $1.94 premarket

** Co says its experimental gene therapy for diabetes, GPX-002, showed encouraging results in early animal studies

** Says therapy improved sugar processing; one primate in study normalized blood sugar after 7 months, another showed improvement but did not fully normalize sugar levels

** Mice normalized within 4 weeks - GNPX

** Co plans more animal studies and aims to seek regulatory nod for human trials

** As of last close, stock up ~3% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment